Successful Bortezomib–Lenalidomide–Dexamethasone Therapy in a 72‐Year‐Old Patient With Sporadic Late‐Onset Nemaline Myopathy Associated With Monoclonal Gammopathy of Muscle Significance
Open Access
- 10 July 2026
- journal article
- case report
- Published by Wiley in Muscle & Nerve
- Vol. 74 (3) , 756-758
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Treatment of AL amyloidosis in the era of novel immune and cellular therapiesFrontiers in Oncology, 2024
- Anti‐cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositisMuscle & Nerve, 2020
- Sporadic late-onset nemaline myopathyNeurology, 2019
- Chemotherapy with stem cell transplantation is more effective than immunotherapy in sporadic late onset nemaline myopathy with monoclonal gammopathyBone Marrow Transplantation, 2018
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialThe Lancet, 2017
- STEM CELL TRANSPLANTATION IN A PATIENT WITH LATE-ONSET NEMALINE MYOPATHY AND GAMMOPATHYNeurology, 2008
- Sporadic late onset nemaline myopathyNeurology, 2005
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982